Josh Jennings, an analyst from TD Cowen, maintained the Buy rating on Abbott Laboratories (ABT – Research Report). The associated price target remains the same with $145.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Josh Jennings has given his Buy rating due to a combination of factors that highlight Abbott Laboratories’ strategic advancements and market positioning. The company’s recent showcase at HRS 2025 demonstrated significant progress in its electrophysiology business, particularly with the introduction of the Volt PFA platform. This platform is designed to address the challenges of first-generation pulsed field technologies, offering a more precise and reliable solution for ablation procedures.
Abbott’s innovative approach with the Volt PFA platform, which includes unique design features and real-time feedback mechanisms, positions the company to capture a larger share of the growing ablation catheter market. The positive clinical data presented at HRS 2025 further supports the potential for increased clinician adoption and sentiment. Additionally, Abbott’s strategic focus on expanding its procedural penetration and leveraging differentiated technologies underscores its capability to achieve above-market growth in the electrophysiology sector.
In another report released on April 21, Argus Research also maintained a Buy rating on the stock with a $150.00 price target.